Twist Bioscience CorpChange company Symbol lookupSelect an option...TWST Twist Bioscience CorpTRIRF Triterras IncAIC Arlington Asset Investment CorpLCID Lucid Group IncAMAT Applied Materials Inc$DWCPAP DJTSM US PaperCMMB Chemomab Therapeutics LtdDLTR Dollar Tree IncBAC Bank of America CorpKW Kennedy-Wilson Holdings IncGo
Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. It consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.
|
|
|
|
| |
TWST's position in the Biotechnology industry
| Industry Peers | PGEN | |
|---|---|---|
Summary | ||
| Company Profile | Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of... | Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company, which is advancing the gene and cell therapies using precision technology to target the urgent and intractable diseases in... Go to PGEN summary |
| 52-Week Change | VS. INDUSTRY | 6.61% |
| Market Cap | VS. INDUSTRY | $329.6M |
| Beta | VS. INDUSTRY | 2.0 |
| Dividend Yield | VS. INDUSTRY | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | -- |
| Data as of | ||
Fundamentals | ||
| Total Revenue (TTM) | VS. INDUSTRY | $23.2M |
| Profit Margin | VS. INDUSTRY | -338.16% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 42.23% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.